News & Latest Announcements
Your Regulatory Dream Team
Navigating the regulatory landscape is one of the most crucial, and often most complex, steps in bringing innovative allogeneic CAR-T therapies to market. For biotech companies…
Read article
Speed Without Compromise: CRO Flexibility
In the rapidly evolving landscape of cell therapy, particularly with the rise of allogeneic (“off-the-shelf”) CAR-T treatments, agility and expertise are no longer optional—they are essential.…
Read article
The High Stakes of Picking the Wrong CRO in Allogeneic Development
Choosing an adequate CRO for an allogeneic cell therapy trial is a critical decision that can determine the success or failure of a program. Allogeneic cell…
Read article
Why Agility is the New Gold Standard in Allogeneic CAR-T Trials
The field of oncology is undergoing a dramatic transformation, driven by the rise of cell therapies. For years, the gold standard was autologous CAR-T therapy, a…
Read article
Advancing Phase I Clinical Research: Our Expertise in PK/PD Studies
Merging Science, Compliance, and Decades of Biosimilar Expertise Phase I clinical research is the foundation of every successful drug development program—determining a compound’s safety, pharmacokinetics (PK),…
Read article
Accelsiors at Swiss Biotech Days 2025: Bridging Innovation, Cultures, and Chocolate
On 5–6 May, Basel buzzed with biotech brilliance as Swiss Biotech Days 2025 united over 3,000 innovators and investors from across theglobe. As a Swiss-headquartered CRO…
Read article
The Future of Early-Phase Clinical Trials: AI, Biomarkers & Smarter Study Designs
A New Era in Early-Phase Trials Early-phase clinical trials—particularly First-in-Human (FIH) and Phase I studies—are the backbone of drug development, determining whether a new treatment is safe,…
Read article
The Festival of Biologics in San Diego – through our Accelsiors lens
This year, Accelsiors had the unique opportunity to participate in the Festival of Biologics USA, held at the San Diego Convention Center on April 23–24. With…
Read article
Biomarkers in Drug Development: Transforming Clinical Trials for Neurodegenerative Diseases
The Role of Biomarkers in Accelerating Drug Development Imagine developing a new drug for Alzheimer’s disease (AD)—only to discover halfway through clinical trials that many participants…
Read article